Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease

References

• Sharma A, Tiwari S, Deb MK, Marty JL. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): a global pandemic and treatments strategies. Int J Antimicrob Agents. 2020;10:106054. doi:10.1016/j.ijantimicag.2020.106054
   Web of Science ®Google Scholar
• Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;28(11):298. doi:10.3389/fmicb.2020.00298
   Web of Science ®Google Scholar
• World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/. Accessed 15 12, 2020.
   Google Scholar
• Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J Formosan Med Assoc. 2020;119(3):670. doi:10.1016/j.jfma.2020.02.00932139299
   PubMed Web of Science ®Google Scholar
• Samrat SK, Tharappel AM, Li Z, Li H. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res. 2020;23:198141. doi:10.1016/j.virusres.2020.198141
   Web of Science ®Google Scholar
• Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225. doi:10.3390/jcm9041225
   PubMed Web of Science ®Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452. doi:10.1038/s41591-020-0820-932284615
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181(2):223–227. doi:10.1016/j.cell.2020.03.03532220310
   PubMed Web of Science ®Google Scholar
• Belete TM. An up-to-date overview of therapeutic agents for the treatment of COVID-19 disease. Clin Pharmacol. 2020;12:203–212. doi:10.2147/CPAA.S28480933363416
   PubMedGoogle Scholar
• Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. MedRxiv. 2020.
   Google Scholar
• Dagotto G, Yu J, Barouch DH. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host Microbe. 2020;28(3):364–370. doi:10.1016/j.chom.2020.08.00232798444
   PubMed Web of Science ®Google Scholar
• Hadjipanayis A, van Esso D, Del Torso S, et al. Vaccine confidence among parents: large scale study in eighteen European countries. Vaccine. 2020;38(6):1505–1512. doi:10.1016/j.vaccine.2019.11.06831848051
   PubMed Web of Science ®Google Scholar
• World Health Organization. DRAFT Landscape of COVID-19 Candidate Vaccines. Geneva: WHO; 2020.
   Google Scholar
• Baviskar T, Raut D, Bhatt LK. Deciphering vaccines for COVID-19: where do we stand today? Immunopharmacol Immunotoxicol. 2020;14:1–48.
   Google Scholar
• Baviskar T, Raut D, Bhatt LK. Deciphering vaccines for COVID-19: where do we stand today? Immunopharmacol Immunotoxicol. 2020;23:1–4.
   Google Scholar
• Belete TM. A review on promising vaccine development progress for COVID-19 disease. Vacunas. 2020;21(2):121–128. doi:10.1016/j.vacun.2020.05.00232837460
   PubMedGoogle Scholar
• Wu D, Koganti R, Lambe UP, Yadavalli T, Nandi SS, Shukla D. Vaccines and therapies in development for SARS-CoV-2 infections. J Clin Med. 2020;9(6):1885. doi:10.3390/jcm9061885
   Web of Science ®Google Scholar
• Morse JS, Lalonde T, Xu S, Liu W. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chem Biochem. 2020;21(5):730–738. doi:10.1002/cbic.202000047
   Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332. doi:10.1056/NEJMoa202692032877576
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. bioRxiv. 2020.
   Google Scholar
• Skwarczynski M, Toth I, editors. Micro-And Nanotechnology in Vaccine Development. William Andrew; 2016.
   Google Scholar
• Wang J, Peng Y, Xu H. The COVID-19 vaccine race: challenges and opportunities in vaccine formulation.
   Google Scholar
• Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–733. doi:10.1016/j.cell.2020.06.03532645327
   PubMed Web of Science ®Google Scholar
• Sumirtanurdin R, MI B. Coronavirus disease 2019 vaccine development: an overview. Viral Immunol. 2020:23.
   Web of Science ®Google Scholar
• Zhang H, Wang G, Li J, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol. 2004;78(13):6938–6945. doi:10.1128/JVI.78.13.6938-6945.200415194770
   PubMed Web of Science ®Google Scholar
• Zhao P, Ke JS, Qin ZL, et al. DNA vaccine of SARS-Cov S gene induces antibody response in mice. Acta Biochim Biophys Sin (Shanghai). 2004;36(1):37–41. doi:10.1093/abbs/36.1.3714732873
   PubMed Web of Science ®Google Scholar
• Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;4:1–8.
   Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.32789505
   PubMed Web of Science ®Google Scholar
• Lim HX, Lim J, Jazayeri SD, Poppema S, Poh CL. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomed J. 2020. doi:10.1016/j.bj.2020.09.005
   Web of Science ®Google Scholar
• Zhang YJ, Zeng G, Pan HX, et al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv. 2020.
   Google Scholar
• Chakraborty R, Parvez S. COVID-19: an overview of the current pharmacological interventions, vaccines, and clinical trials. Biochem Pharmacol. 2020;30:114184. doi:10.1016/j.bcp.2020.114184
   Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.32789505
   PubMed Web of Science ®Google Scholar
• Rawat K, Kumari P, Saha L. COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2020;25:173751.
   Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020;21(1):15. doi:10.1016/S1473-3099(20)30831-8
   Web of Science ®Google Scholar
• Dutta AK. Vaccine against Covid-19 disease–present status of development. Indian J Pediatrics. 2020;3:1–7.
   Google Scholar
• Dai X, Xiong Y, Li N, Jian C. Vaccine Types Vaccines-The History and Future. 2019.
   Google Scholar
• Cao Z, Liu L, Du L, et al. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010;7(1):1–6. doi:10.1186/1743-422X-7-29920044930
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676. doi:10.1128/JVI.78.22.12672-12676.200415507655
   PubMed Web of Science ®Google Scholar
• Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2. F1000Research. 2020;9.32742638
   PubMedGoogle Scholar
• Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. Virus Res. 2020;13:198114. doi:10.1016/j.virusres.2020.198114
   Web of Science ®Google Scholar
• Smith TR, Schultheis K, Broderick KE. Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods. Hum Vaccin Immunother. 2017;13(11):2626–2629. doi:10.1080/21645515.2017.136313428881156
   PubMed Web of Science ®Google Scholar
• Piyush R, Rajarshi K, Chatterjee A, Khan R, Ray S. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon. 2020;19:e05007. doi:10.1016/j.heliyon.2020.e05007
   Web of Science ®Google Scholar
• Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14(10):12522–12537. doi:10.1021/acsnano.0c0719733034449
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920–1931. doi:10.1056/NEJMoa202248332663912
   PubMed Web of Science ®Google Scholar
• Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development. Med Sci Monitor. 2020;26:e924700–1. doi:10.12659/MSM.924700
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383(16):1544–1555. doi:10.1056/NEJMoa202467132722908
   PubMed Web of Science ®Google Scholar
• Saini P. COVID-19 pandemic: potential phase III vaccines in development. T Appl Biol Chem J. 2020;1(1):21–33.
   Google Scholar
• Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31(2):180–188. doi:10.1097/CJI.0b013e31815ce50118481387
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;17:371.
   Google Scholar
• Walsh EE, Frenck R, Falsey AR, et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. Medrxiv. 2020. doi:10.1101/2020.08.17.20176651
   Google Scholar
• Mahase E. Covid-19: UK Approves Pfizer and BioNTech Vaccine with Rollout Due to Start Next Week.
   Google Scholar
• Banday AH, Shameem SA, Ajaz SJ. Potential repurposed therapeutics and new vaccines against COVID-19 and their clinical status. SLAS DISCOVERY. 2020;25(10):1097–1107.32692266
   PubMed Web of Science ®Google Scholar
• Gary EN, Weiner DB. DNA vaccines: prime time is now. Curr Opin Immunol. 2020;65:21–27. doi:10.1016/j.coi.2020.01.00632259744
   PubMed Web of Science ®Google Scholar
• Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARSCoV- 2 vaccine pipeline: an overview. Current Tropical Med Rep. 2020;7(2):61–64. doi:10.1007/s40475-020-00201-6
   PubMedGoogle Scholar
• ClinicalTrials.gov. Identifier: NCT4336410. 2020 Available from: https://clinicaltrials.gov/ct2/show/NCT4336410. Accessed 52, 2020
   Google Scholar
• Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709–722. doi:10.1016/j.ymthe.2020.01.00131968213
   PubMed Web of Science ®Google Scholar
• Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5(1):1–6. doi:10.1038/s41541-020-00221-3
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.32789505
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;396(10249):479–488. doi:10.1016/S0140-6736(20)31605-6
   PubMed Web of Science ®Google Scholar
• Alturki SO, Alturki SO, Connors J, et al. The 2020 Pandemic: current SARS-CoV-2 vaccine development. Front Immunol. 2020;11.32082309
   PubMed Web of Science ®Google Scholar
• Covid-vaccine-tracker, COVID-19 Vaccine & Therapeutics Tracker, 2020 Available from: https://biorender.com/covid-vaccine-tracker/details/v-0CV3/bacille-calmette-guerin-bcg. Accessed 52, 2020
   Google Scholar
• Siddique R, Bai Q, Shereen MA, et al. Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. Hum Vaccin Immunother. 2020;5:1–9. doi:10.1080/21645515.2020.1824497
   Web of Science ®Google Scholar
• Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and drug therapeutics to lock down novel Coronavirus Disease 2019 (COVID-19): a systematic review of clinical trials. Cureus. 2020;12:5.
   Web of Science ®Google Scholar
• Petersen E, Wejse C, Zumla A. Advancing COVID-19 vaccines–avoiding different regulatory standards for different vaccines and need for open and transparent data sharing. Int J Infect Dis. 2020;98:501–502. doi:10.1016/j.ijid.2020.08.04332822866
   PubMed Web of Science ®Google Scholar
• Balakrishnan VS. The arrival of Sputnik V. Lancet Infect Dis. 2020;20(10):1128. doi:10.1016/S1473-3099(20)30709-X32979327
   PubMed Web of Science ®Google Scholar
• Burki TK. The Russian vaccine for COVID-19. Lancet Respir Med. 2020;5.31628086
   PubMed Web of Science ®Google Scholar
• Advancing COVID-19 vaccines – avoiding different regulatory standards for different vaccines and need for open and transparent data sharing.
   Google Scholar
• van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810–812. doi:10.1038/s41563-020-0746-032704139
   PubMed Web of Science ®Google Scholar
• Karpiński TM, Ożarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D. The 2020 race towards SARS-CoV-2 specific vaccines.
   Google Scholar
• Bakhiet M, Taurin S. SARS-CoV-2: targeted managements and vaccine development. Cytokine Growth Factor Rev. 2020. doi:10.1016/j.cytogfr.2020.11.001
   Web of Science ®Google Scholar
• Medicago announces production of a viable vaccine candidate for COVID-19. BioSpace. Available from: https://www.biospace.com/article/releases/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19/. Accessed 5 24, 2020
   Google Scholar